0.32 (-19.95%)
As of Dec 11, 2023
Source:
Evelo Biosciences is discovering and developing a new class of orally delivered investigational medicines that are intended to act on cells in the small intestine to produce therapeutic effects throughout the body. The target cells in the small intestine play a central role in governing human immune, metabolic and neurologic systems. We refer to this biology as the small intestinal axis, or SINTAX. We have built a platform to discover and develop novel oral medicines which target the small intestinal axis.
Country | United States |
Headquarters | cambridge, massachusetts |
Phone Number | 617-577-0300 |
Industry | manufacturing |
CEO | Balkrishan Gill |
Website | www.evelobio.com |